Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724009 · ClinicalTrials.gov registry record · Phase 2
Clofarabine Bone Marrow Cytoreduction
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00724009 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 29 participants.
The verdict
NCT00724009, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.
Interventions
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724009
The ClinicalTrials.gov registry entry for NCT00724009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clofarabine is the first listed.
NCT00724009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724009 about?
NCT00724009 is a clinical study titled "Clofarabine Bone Marrow Cytoreduction". For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant relate...
What is the current status of trial NCT00724009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00724009?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00724009?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.